Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab Phase 1 in Advanced Solid Tumors
NCT02857166Phase 1Completed
- Sponsor
- Shanghai Junshi Biosciences Co., Ltd.
- Start
- Mar 2016
- Primary completion
- Sep 2017
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of toripalimab in solid tumor, sponsored by Shanghai Junshi Biosciences Co., Ltd. Primary endpoint: Number of Participants With Abnormal Laboratory Values and/or Adverse Events That Are Related to Treatment up to 2 years. Started Mar 2016; status: completed.
02
Drugs
toripalimab
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT02857166.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02857166.